Project Somnum's "core product is its Brain Anaesthesia Response Monitor (BARM), which received Australian Therapeutic Goods Administration (TGA) and European CE Mark approvals in 2015" the article states.
"The company is currently focused on ramping up sales in Australia, New Zealand,South Korea, Europe and the UK...It will be appointing distributors in targeted European markets."
"The brain anaesthesia monitoring market is expected to be valued at USD 1.6bn in 2020, while the pain monitoring market is expected to be valued at USD 8.6bn by 2022."
Please read the full Mergermarket article via the link below.
To find out more about Project Somnum, please contact us.